Government to pay half of nation's health care costs within next decade: study

Share this article:
A new study shows that the government’s contribution to the nation’s healthcare tab, already at 45%, is expected to approach 50% within the next 10 years, The Wall Street Journal reports. Overall health spending in the US is expected to double to $4.1 trillion by 2016, consuming 20% of the nation’s gross domestic product, up from the current 16%, data from the federal study show. By then, the study predicts, the government will be paying 48.7% of the nation’s healthcare bill, up from 38% in 1970 and 40% in 1990. According to the study’s projections, Medicare spending grew by 22% to $418 billion in 2006, up from $342 billion in 2005. The study said the growth would slow to 6.5% this year, due to scheduled cuts in payments to physicians and smaller payment increases to managed care Medicare Advantage plans, which cover other benefits as well as drugs. Drug companies have profited from the drug benefit. In the first seven months of 2006, prescriptions funded by Medicare drug plans accounted for nearly 9% of medicines bought in retail pharmacies, The Journal reported, citing data from prescription data tracking firm Verispan. One of the biggest winners was Bristol-Myers Squibb. Nearly 14% of US retail prescriptions for its drugs, particularly Plavix, were financed by the Medicare drug benefit during that period, according to Verispan. Medicare funded prescriptions accounted for more than 10% of AstraZeneca’s and Merck’s prescriptions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...